Rocky Mountain Hospice Medicare Approved Location: 5242 South College Drive, Suite 150, Murray, Utah 84123 Phone: (801) 397-4900 |
Harmony Hospice Medicare Approved Location: 5650 Green Street, Murray, Utah 84123 Phone: (801) 281-0537 |
Encompass Hospice Of Utah Medicare Approved Location: 990 West Bellwood Lane, Murray, Utah 84123 Phone: (801) 747-5500 |
Superior Hospice Medicare Approved Location: 184 East 5900 South, Murray, Utah 84107 Phone: (801) 254-3200 |
Inspiration Hospice, Llc Medicare Approved Location: 835 East 4800 South, Suite 110, Murray, Utah 84107 Phone: (801) 281-1314 |
Silverado Hospice-salt Lake City Medicare Approved Location: 855 East 4800 South, Suite 240, Murray, Utah 84107 Phone: (801) 506-1500 |
Summit Hospice Medicare Approved Location: 5882 South 900 East, Suite 101, Murray, Utah 84121 Phone: (801) 542-7150 |
Brighton Hospice Medicare Approved Location: 1106 East 6600 South, Suite 100, Murray, Utah 84121 Phone: (801) 930-5266 |
Cornerstone Hospice Medicare Approved Location: 5292 South College Drive, Suite 304, Murray, Utah 84123 Phone: (801) 716-7800 |
News Archive
The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.
Hanli Liu, a professor of bioengineering at The University of Texas at Arlington, is working to improve memory and cognitive function in astronauts during space missions by directing light onto their brains.
Two studies are of particular note in today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO): a report by Swiss neuro-ophthalmic researchers about vision exam clues that should make ophthalmologists suspect an atypical variant of Alzheimer's disease; and new evidence from a Singapore National Eye Center study that diabetics who are nearsighted may be less susceptible to diabetic retinopathy.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the second quarter of 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.01 per share for the thirteen week period ended July 3, 2010.
› Verified 3 days ago